Pregabalin as an add-on Therapy to Carbamazepine in Trigeminal Neuralgia Patients

Launched by POSTGRADUATE INSTITUTE OF DENTAL SCIENCES ROHTAK · Apr 4, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called pregabalin when added to the standard treatment of carbamazepine for patients suffering from trigeminal neuralgia, a condition known for causing intense facial pain. Carbamazepine is commonly used to treat this condition, but it can have side effects like drowsiness and liver issues. The researchers want to see if adding pregabalin, which is known for treating nerve pain and is easier to manage, can provide better pain relief and improve the overall quality of life for patients.

To participate in the trial, patients must be diagnosed with classical trigeminal neuralgia and agree to take part in the study. Those who are pregnant, have liver or kidney problems, or are taking certain other medications will not be eligible. The trial will involve 50 participants who will be divided into two groups. One group will receive both carbamazepine and pregabalin, while the other group will receive carbamazepine alone. The researchers will monitor the patients for pain relief, quality of life, and any side effects from the treatments. This study aims to find out if the combination of these two medications is more effective than carbamazepine alone.

Gender

ALL

Eligibility criteria

• • INCLUSION CRITERIA
• • Patients diagnosed with Trigeminal neuralgia with classical types without concomitant pain as per ICHD-II.
• • Patient's consent for participation in this study.
• • EXCLUSION CRITERIA
• • Pregnant and lactating women
• • Patients on anti-depressants like sodium valproate
• • History of excessive alcohol intake
• • Hepatic or renal insufficiency
• • Known tolerance/allergy to study drug
• • Non -compliant during screening period
• • Any other hepatic microsomal enzyme inhibitors (to avoid risk for toxicity)